Gut-lung axis in COPD: mechanisms of persistent inflammation and therapeutic implications
This narrative review maps gut-lung axis pathophysiological mechanisms in COPD but does not establish causality or clinical efficacy of any microbiota-targeted intervention.
| Population | Adults with COPD (no restriction by stage or severity) and animal models of cigarette smoke exposure |
|---|---|
| Intervention | Gut dysbiosis, reduced SCFAs, impaired intestinal barrier, LPS translocation, Th17/Treg immune imbalance; interventions: probiotics, prebiotics, diet, fecal microbiota transplantation, Chinese medicine |
| Comparator | Healthy controls (observational studies) or no intervention (animal models); no standardized active comparator in cited clinical trials |
| Outcome | Gut microbiota beta diversity; Abundance of SCFA-producing bacteria and fecal acetate; Pulmonary Th17/Treg imbalance in animal models; COPD risk by specific microbial taxa (Holdemanella) — Mendelian randomization; Lung function (FEV1/FVC) as outcome of microbiota interventions; Exacerbation rate as outcome of microbiota interventions; Systemic inflammation (circulating biomarkers) in COPD and dysbiosis |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Gut microbiota beta diversity | reduced beta diversity in COPD vs healthy controls; in the pooled effect size reported | — | Low | — | |
| Abundance of SCFA-producing bacteria and fecal acetate | decreased SCFA-producing bacteria and fecal acetate in COPD; correlation with lung function reported without pooled OR/RR or 95% CI | — | Low | — | |
| Pulmonary Th17/Treg imbalance in animal models | gut dysbiosis associated with pulmonary Th17/Treg imbalance in rodent models; partial improvement with microbiota modulation; in the quantitative effect size | — | Very low | — | |
| COPD risk by specific microbial taxa (Holdemanella) — Mendelian randomization | Holdemanella associated with increased COPD risk in Mendelian randomization; direction reported, in the pooled OR/RR or 95% CI provided in this review | — | Low | — | |
| Lung function (FEV1/FVC) as outcome of microbiota interventions | no RCT-level pooled effect size reported; evidence insufficient to determine direction of effect for clinical interventions | — | Very low | — | |
| Exacerbation rate as outcome of microbiota interventions | no pooled RR or 95% CI reported; insufficient RCT evidence | — | Very low | — | |
| Systemic inflammation (circulating biomarkers) in COPD and dysbiosis | LPS translocation and reduced SCFAs associated with elevated systemic inflammatory markers in observational and animal studies; in the pooled effect size with 95% CI | — | Low | — |
Context
COPD remains a leading global cause of mortality and disability, with current therapies unable to halt disease progression or control systemic inflammation. Accumulating evidence links intestinal dysbiosis, reduced SCFA-producing bacteria, and impaired gut barrier function to amplified pulmonary inflammation. Understanding the gut-lung axis may guide adjunctive strategies, but causal chains remain unproven.
What the study showed
The review synthesizes evidence that COPD patients show reduced gut microbiota beta diversity and lower abundance of SCFA-producing bacteria compared with healthy controls, with correlations reported between fecal acetate and pulmonary function parameters but without consolidated effect sizes. Animal models show that cigarette smoke exposure induces gut dysbiosis alongside pulmonary inflammation, and that microbiota modulation can partially improve pulmonary Th17/Treg imbalance. Mendelian randomization studies suggest an association between specific taxa (Holdemanella) and increased COPD risk. No RCT with validated primary endpoints is presented as definitive evidence of efficacy for any intervention.
How it was done
Narrative review published in Frontiers in Immunology (2026); no registered protocol, no explicit systematic search, no formal inclusion/exclusion criteria, and no quantitative synthesis. Incorporates observational studies, animal models, Mendelian randomization studies, and preliminary clinical trials without stratification by methodological quality. AMSTAR-2 or equivalent not applied.
Effect magnitude
No aggregated effect size (RR, OR, SMD, MD) with 95% CI is reported; correlations between microbiota and lung function are mentioned without consolidated numerical values, leaving overall effect magnitude indeterminate.
Risk of bias
Narrative review without registered protocol, systematic search, or formal risk-of-bias assessment (AMSTAR-2 not applied); study selection potentially subject to confirmation bias. Heterogeneity across populations, microbiota characterization methods, and outcomes precludes generalization. Causality between dysbiosis and COPD is unestablished: observational studies cannot distinguish cause from disease consequence.
What this study does NOT prove
This review does not prove causality between gut dysbiosis and COPD progression, nor clinical efficacy of any microbiota-targeted intervention. It is not applicable to individual therapeutic decisions without support from RCTs with clinically relevant endpoints.
In clinical practice
No grade A or B evidence justifies modifying clinical protocols based solely on the gut-lung axis. Clinicians should maintain standard treatment (bronchodilators, inhaled corticosteroids, smoking cessation, pulmonary rehabilitation). Microbiota interventions (probiotics, diet, FMT) remain experimental and must not replace established management.
Limitations
Narrative review without registered protocol, systematic search, or formal risk-of-bias assessment (AMSTAR-2 not applied); study selection potentially subject to confirmation bias. Heterogeneity across populations, microbiota characterization methods, and outcomes precludes generalization. Causality between dysbiosis and COPD is unestablished: observational studies cannot distinguish cause from disease consequence.
What is still missing
RCTs with validated primary endpoints (FEV1, exacerbation rate, mortality) are needed to confirm efficacy of gut-lung axis interventions in COPD. Longitudinal cohort studies with multi-omics sequencing are needed to establish temporality and causality.
Technical appendix
Version history
- 1.0 · 2026-11-18 — Auto-generated under Evidence Standard v1.0
